OncoMatch

OncoMatch/Clinical Trials/NCT06665100

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Is NCT06665100 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PUL-042 for hematologic malignancies.

Phase 2RecruitingPulmotect, Inc.NCT06665100Data as of May 2026

Treatment: PUL-042 — The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Prior therapy

Must have received: cytotoxic chemotherapy

Subjects who have undergone active cytotoxic chemotherapy within 6 months

Must have received: immunosuppressive therapy (alemtuzumab, ibrutinib, mycophenolate mofetil, corticosteroids)

subjects who are on an immunosuppressive therapy (e.g., alemtuzumab, ibrutinib, mycophenolate mofetil, corticosteroids ≥1mg/kg prednisone equivalent)

Cannot have received: investigational agent

Exposure to any investigational agent (defined as any non-FDA-approved agent) within 30 days, or 5 half-lives of the investigational agent, whichever is longer, prior to the Screening Visit

Cannot have received: PUL-042 Inhalation Solution (PUL-042)

Previous exposure to PUL-042 Inhalation Solution

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope National Medical Center · Duarte, California
  • Northside Hospital · Atlanta, Georgia
  • Johns Hopkins Hospital · Baltimore, Maryland
  • Brigham and Women's Hospital · Boston, Massachusetts
  • Barbara Ann Karmanos Cancer Institute · Detroit, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify